Sign In
Buy QTTB
$15.68
+0.120 (+0.771%)
At Close: Jul 31, 2026
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet
10:56am, Friday, 31'st Jul 2026
The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Playing The Biotech Breakout With Insiders
03:15pm, Thursday, 23'rd Jul 2026
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Al
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
01:01pm, Monday, 20'th Jul 2026
Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Q32 Bio: Bempikibart's Progress Keeps Me Bullish
08:00am, Friday, 17'th Jul 2026
Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits appear
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
10:55am, Wednesday, 15'th Jul 2026
The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
10:58pm, Tuesday, 14'th Jul 2026
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other a
Why Q32 Bio Stock Skyrocketed Today
09:38pm, Monday, 13'th Jul 2026
The biotech is advancing a potential treatment for a common autoimmune disease.
Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts
04:01pm, Monday, 13'th Jul 2026
Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Monday, 13'th Jul 2026
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and
Why Q32 Bio investors should take profits in the stock after 81% rally
01:15pm, Monday, 13'th Jul 2026
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial. The trial that evaluated its anti-IL-7R
Q32 Bio's Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Study
12:02pm, Monday, 13'th Jul 2026
Q32 Bio NASDAQ: QTTB reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata, a d
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why
08:55am, Monday, 13'th Jul 2026
Q32 Bio Inc. (NASDAQ:QTTB) stock is trading higher on Monday after the clinical-stage biotechnology company shared positive 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial.
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
06:59am, Monday, 13'th Jul 2026
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis -- -- 40.0% of patients
-- Conference call to be held Monday, July 13 th at 8:00 a.m. E.T. -- WALTHAM, Mass.
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
09:18am, Thursday, 28'th May 2026
I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts. Company expects mid-2026 data from both Part B [36-week topline] and Part A OLE of it
